Loading...
XJPX4595
Market cap176mUSD
Jan 17, Last price  
1,449.00JPY
1D
-1.56%
1Q
-13.34%
Jan 2017
152.77%
IPO
133.71%
Name

Mizuho Medy Co Ltd

Chart & Performance

D1W1MN
XJPX:4595 chart
P/E
7.31
P/S
2.51
EPS
198.14
Div Yield, %
8.28%
Shrs. gr., 5y
—
Rev. gr., 5y
11.33%
Revenues
10.99b
-37.49%
3,248,000,0003,997,355,0004,083,053,0004,962,189,0005,623,976,0006,425,082,0006,426,910,0004,203,303,00012,886,270,00017,581,830,00010,989,735,000
Net income
3.77b
-51.85%
139,000,000317,297,000257,601,000395,205,000660,049,000919,205,000874,344,000306,346,0004,816,772,0007,838,094,0003,774,239,000
CFO
3.99b
-35.33%
0215,830,00017,712,000187,282,000877,678,000670,668,000745,001,000295,417,0005,596,506,0006,172,506,0003,991,831,000
Dividend
Dec 27, 202440 JPY/sh

Profile

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.
URL
https://www.mizuho-m.co.jp/
IPO date
Dec 17, 2015
Employees
175
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,989,735
-37.49%
17,581,830
36.44%
Cost of revenue
5,789,416
4,662,674
Unusual Expense (Income)
NOPBT
5,200,319
12,919,156
NOPBT Margin
47.32%
73.48%
Operating Taxes
1,518,232
3,232,791
Tax Rate
29.19%
25.02%
NOPAT
3,682,087
9,686,365
Net income
3,774,239
-51.85%
7,838,094
62.73%
Dividends
(2,380,827)
(1,570,630)
Dividend yield
7.96%
4.40%
Proceeds from repurchase of equity
(177)
(106)
BB yield
0.00%
0.00%
Debt
Debt current
(18,477)
Long-term debt
Deferred revenue
Other long-term liabilities
992,920
897,445
Net debt
(10,150,764)
(8,730,281)
Cash flow
Cash from operating activities
3,991,831
6,172,506
CAPEX
(270,067)
(179,282)
Cash from investing activities
(270,448)
(1,553,587)
Cash from financing activities
(2,381,004)
(1,570,737)
FCF
2,597,810
7,770,725
Balance
Cash
10,134,764
8,702,146
Long term investments
16,000
9,658
Excess cash
9,601,277
7,832,712
Stockholders' equity
15,213,935
14,041,253
Invested Capital
7,067,246
4,763,720
ROIC
62.24%
257.11%
ROCE
31.20%
102.56%
EV
Common stock shares outstanding
9,524
9,524
Price
3,140.00
-16.27%
3,750.00
59.03%
Market cap
29,906,742
-16.27%
35,716,751
59.03%
EV
19,755,978
26,986,470
EBITDA
5,444,141
13,105,750
EV/EBITDA
3.63
2.06
Interest
Interest/NOPBT